• 提示：详情请下载说明书。

• 产品描述： The inhibition of cell (including human SCLC cell line SBC-3 and human NSCLC cell line PC-14) proliferation after drug treatments as the antitumor activity using a regrowth assay is messured. Briefly, cells are exposed to drugs alone or in combination for 6 days at 37°C in an atmosphere of 100% humidity with 5% CO2; the cells are then pipetted six to eight times until almost all cells appeared as single cells and counted with a counter. For each drug, concentration-effect curves are drawn as plots of the fraction of surviving cells (unaffected cell fraction, fu) versus drug concentration. The cell proliferation ratio of the treated:control cultures (T:C%) is calculated as follows: [(the number of treated cells on day 6)/(the number of treated cells on day 0)]/[(the number of control cells on day 6)/(the number of control cells on day 0)] × 100%. The IC50 is defined as the drug concentration required for a 50% reduction in the number of cells. Four or five independent experiments are carried out for each. To check the effect of the drug treatment schedule on the effect of the combination, the cells are treated either by simultaneous exposure to the two drugs or by sequential exposure to Nedaplatin followed by irinotecan (Nedaplatin→irinotecan) and vice versa (irinotecan→Nedaplatin) for 3 hours. For the sequential exposure treatment, cells are exposed to the first drug for 3 hours, ished in fresh medium once, and then immediately exposed to the second drug for 3 hours. The treated cells are cultured in drug-free medium until evaluation.(Only for Reference)

• 靶点： DNA/RNA Synthesis

• 体内研究： Nedaplatin (Aqupla)是顺铂衍生物,能抑制肿瘤克隆集落形成（IC50：28.5 μg/mL）。0.005-0.5 μg/mL的Nedaplatin对SBC-3细胞增殖的抑制效果为2%-98%（IC50：0.053 μg/mL）

• 细胞实验： The inhibition of cell (including human SCLC cell line SBC-3 and human NSCLC cell line PC-14) proliferation after drug treatments as the antitumor activity using a regrowth assay is messured. Briefly, cells are exposed to drugs alone or in combination for 6 days at 37°C in an atmosphere of 100% humidity with 5% CO2; the cells are then pipetted six to eight times until almost all cells appeared as single cells and counted with a counter. For each drug, concentration-effect curves are drawn as plots of the fraction of surviving cells (unaffected cell fraction, fu) versus drug concentration. The cell proliferation ratio of the treated:control cultures (T:C%) is calculated as follows: [(the number of treated cells on day 6)/(the number of treated cells on day 0)]/[(the number of control cells on day 6)/(the number of control cells on day 0)] × 100%. The IC50 is defined as the drug concentration required for a 50% reduction in the number of cells. Four or five independent experiments are carried out for each. To c

• 参考文献：
  1.Alberts DS, et al. Cancer Chemother Pharmacol, 1997, 39(6), 493-497. 2.Matsumoto M, et al. Jpn J Cancer Res, 2001, 92(1), 51-58. 3.Kanzawa F, et al. Clin Cancer Res, 2001, 7(1), 202-209. 4.Wheate NJ et al. Dalton Trans, 2010, 39(35), 8113-8127. 5.Uchida N, et al.Eur J Cancer, 1998, 34(11), 1796-1801.

• 溶解性： DMSO:Insoluble    H2O:10  mM

• 保存条件： -20℃

• 配置溶液浓度参考：
  

  	1mg	5mg	10mg
  1 mM	3.298 ml	16.492 ml	32.985 ml
  5 mM	0.66 ml	3.298 ml	6.597 ml
  10 mM	0.33 ml	1.649 ml	3.298 ml
  50 mM	0.066 ml	0.33 ml	0.66 ml

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *